Insights

Innovative Pipeline Surface Oncology focuses on next-generation immuno-oncology therapies targeting the tumor microenvironment, presenting opportunities to collaborate on novel antibody discovery and immune modulation solutions for cancer treatment.

Strategic Merger The recent merger with Coherus BioSciences expands Surface's market reach and development capabilities, indicating potential for joint ventures or licensing deals to accelerate clinical development and commercialization efforts.

Research & Development Focus With an aggressive approach to antibody generation and deep biological insights, Surface offers opportunities to supply specialized reagents, technical services, or collaborative research support to enhance drug discovery projects.

Clinical Progress Active clinical trial phases and recent study advancements suggest a demand for advanced diagnostic tools, biomarker assays, and data analytics services to support clinical trials and patient monitoring.

Financial & Growth Potential Although revenue is modest with substantial funding, Surface’s expanding pipeline and strategic partnerships provide a promising landscape for targeted sales of research tools, collaboration services, and therapeutic development support.

Surface Oncology Inc. Tech Stack

Surface Oncology Inc. uses 8 technology products and services including SiteCatalyst, Tableau, Webpack, and more. Explore Surface Oncology Inc.'s tech stack below.

  • SiteCatalyst
    Analytics
  • Tableau
    Business Intelligence
  • Webpack
    Development
  • Mimecast
    Email Security
  • Web Vitals
    Javascript Libraries
  • Akamai Web Application Protector
    Security
  • Adobe Creative Suite
    Visualisation Software
  • Popup Maker
    Web Platform Extensions

Media & News

Surface Oncology Inc.'s Email Address Formats

Surface Oncology Inc. uses at least 1 format(s):
Surface Oncology Inc. Email FormatsExamplePercentage
FLast@surfaceoncology.comJDoe@surfaceoncology.com
49%
Last@surfaceoncology.comDoe@surfaceoncology.com
2%
FLast@surfaceoncology.comJDoe@surfaceoncology.com
49%

Frequently Asked Questions

Where is Surface Oncology Inc.'s headquarters located?

Minus sign iconPlus sign icon
Surface Oncology Inc.'s main headquarters is located at 50 Hampshire Street, 8th Floor. The company has employees across 4 continents, including North AmericaAsiaEurope.

What is Surface Oncology Inc.'s phone number?

Minus sign iconPlus sign icon
You can contact Surface Oncology Inc.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Surface Oncology Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Surface Oncology Inc.'s official website is surfaceoncology.com and has social profiles on LinkedInCrunchbase.

What is Surface Oncology Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
Surface Oncology Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Surface Oncology Inc. have currently?

Minus sign iconPlus sign icon
As of December 2025, Surface Oncology Inc. has approximately 51 employees across 4 continents, including North AmericaAsiaEurope. Key team members include President: A. J. B.Author And Owner: K. W.Senior Director Toxicology: C. R.. Explore Surface Oncology Inc.'s employee directory with LeadIQ.

What industry does Surface Oncology Inc. belong to?

Minus sign iconPlus sign icon
Surface Oncology Inc. operates in the Biotechnology Research industry.

What technology does Surface Oncology Inc. use?

Minus sign iconPlus sign icon
Surface Oncology Inc.'s tech stack includes SiteCatalystTableauWebpackMimecastWeb VitalsAkamai Web Application ProtectorAdobe Creative SuitePopup Maker.

What is Surface Oncology Inc.'s email format?

Minus sign iconPlus sign icon
Surface Oncology Inc.'s email format typically follows the pattern of FLast@surfaceoncology.com. Find more Surface Oncology Inc. email formats with LeadIQ.

How much funding has Surface Oncology Inc. raised to date?

Minus sign iconPlus sign icon
As of December 2025, Surface Oncology Inc. has raised $29M in funding. The last funding round occurred on May 20, 2020 for $29M.

When was Surface Oncology Inc. founded?

Minus sign iconPlus sign icon
Surface Oncology Inc. was founded in 2014.

Surface Oncology Inc.

Biotechnology ResearchMassachusetts, United States51-200 Employees

Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors", have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit. We believe that the lack of a broad and sustained clinical response is because these first-generation therapies only target one component of the immunosuppressive TME and a broader, more multi-faceted therapeutic approach is required. 
We are a team on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families.
Surface is leveraging its deep understanding of TME biology to target factors and cells that suppress patients’ anti-tumor immune response. Our broad attack on the TME has the potential to convert patients’ non-responsive ‘cold’ tumors into immune-active ones. We push ourselves to break through across all dimensions of our work.  
From a discovery perspective, Surface leverages its world-class SAB to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies, which allows our scientists to thoroughly explore the relevant biology. Our antibody discovery approach generates therapeutic-quality antibodies, as well as unique tools to explore the biology of the tumor microenvironment.

Section iconCompany Overview

Headquarters
50 Hampshire Street, 8th Floor
Phone number
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2014
Employees
51-200

Section iconFunding & Financials

  • $29M

    Surface Oncology Inc. has raised a total of $29M of funding over 4 rounds. Their latest funding round was raised on May 20, 2020 in the amount of $29M.

  • $1M$10M

    Surface Oncology Inc.'s revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $29M

    Surface Oncology Inc. has raised a total of $29M of funding over 4 rounds. Their latest funding round was raised on May 20, 2020 in the amount of $29M.

  • $1M$10M

    Surface Oncology Inc.'s revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.